Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

Sensitive, scalable and affordable measurable residual disease (MRD) assays are needed to guide treatment decisions in acute myeloid leukemia (AML), particularly around allogeneic hematopoietic stem cell transplantation (allo-SCT). Next-generation sequencing (NGS)-based MRD assays offer broad appli...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Simon M. Krauß, Tara Holloway, Anne Weigert, Lara Bischof, Donata Backhaus, Dominic Brauer, Jule Ussmann, Georg-Nikolaus Franke, Vladan Vučinić, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch, Klaus H. Metzeler
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Ferrata Storti Foundation 2026-05-01
Cyfres:	Haematologica
Mynediad Ar-lein:	https://haematologica.org/article/view/14203
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!